Breast Cancer Clinical Trial
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
Summary
This is a phase 2, open-label, multicenter, 2-arm study of bosutinib administered in combination with exemestane versus exemestane alone. This is a 2-part study consisting of a safety lead-in phase and randomized phase 2 portion. Subjects in part 1 will receive bosutinib and exemestane daily, and will be closely monitored for 28 days. If no safety concerns arise, then future eligible subjects will be randomly assigned to the main phase of the study. They will either receive bosutinib daily combined with daily exemestane, or daily exemestane alone for a specified period of time. Subjects will be followed up for survival after treatment discontinuation.
Full Description
This study was terminated on 19 Apr 2010 due to unfavorable risk benefit ratio which did not support continuation in part 2 of the study. Even if the safety profile of the combination of Bosutinib and Exemestane was acceptable 25% of subjects had treatment related liver events including 14% of severe liver events.
Eligibility Criteria
Inclusion Criteria:
Woman aged 18 years or older.
Confirmed pathologic diagnosis of breast cancer.
Locally advanced, metastatic, or locoregional recurrent breast cancer not amenable to curative treatment with surgery or radiotherapy.
Surgically sterile or postmenopausal woman.
Documented ER+ and/or PgR+ and erbB2- tumor.
Progression of locally advanced or metastatic disease during treatment with a nonsteroidal AI or tamoxifen, or progression during treatment with (or within 6 months of discontinuation of) an adjuvant nonsteroidal AI.
Exclusion Criteria:
Prior exemestane, prior bosutinib, or any other prior anti-Src therapy.
More than 1 prior endocrine treatment for locally advanced or MBC.
More than 1 prior cytotoxic chemotherapy regimen in metastatic setting.
Bone or skin as the only site of disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 25 Locations for this study
Lake Worth Florida, 33461, United States
Joliet Illinois, 60435, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02115, United States
Detroit Michigan, 84202, United States
New Brunswick New Jersey, 08901, United States
New York New York, 10032, United States
Bethlehem Pennsylvania, 18015, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19104, United States
Seattle Washington, 98104, United States
South Brisbane Queensland, 4101, Australia
Brussels , 1000, Belgium
Leuven , 3000, Belgium
Liege , 4000, Belgium
Wilrijk , 2610, Belgium
Kelowna British Columbia, V1Y 5, Canada
Beijing , 10002, China
Hong Kong , , Hong Kong
Budapest , 1122, Hungary
Mumbai Maharashtra, 40001, India
Pune Maharashtra, 41100, India
Olsztyn , 10-51, Poland
Lynnwood Gauteng, 0081, South Africa
Barcelona , 08035, Spain
Madrid , 28040, Spain
Valencia , 46010, Spain
, ,
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.